HRS-3738
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Conditions
Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Trial Timeline
Jun 17, 2022 → Dec 30, 2024
NCT ID
NCT05363800About HRS-3738
HRS-3738 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05363800. Target conditions include Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05363800 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma